- Report
- August 2018
- 20 Pages
Global
From €9667EUR$10,000USD£8,309GBP
- Report
- February 2024
- 72 Pages
Global
From €3500EUR$3,878USD£3,114GBP
- Report
- April 2024
- 50 Pages
Global
From €2562EUR$2,650USD£2,202GBP
- Book
- May 2023
- 512 Pages
Bortezomib is a type of oncology drug used to treat multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. It is a proteasome inhibitor, meaning it works by blocking the activity of proteasomes, which are responsible for breaking down proteins in cells. Bortezomib is administered intravenously or subcutaneously, and is usually given in combination with other drugs. It is also used to treat mantle cell lymphoma, a type of non-Hodgkin's lymphoma.
Bortezomib is a relatively new drug, having been approved by the FDA in 2003. It has been found to be effective in treating multiple myeloma, and is now considered a standard of care for the disease. It has also been found to be effective in treating mantle cell lymphoma, and is being studied for its potential use in other types of cancer.
Some companies in the Bortezomib market include Janssen Biotech, Inc., Millennium Pharmaceuticals, Inc., and Onyx Pharmaceuticals, Inc. Show Less Read more